To The Moon

$Johnson & Johnson(JNJ)$ is set to announce its fiscal third-quarter 2025 earnings on Tuesday, October 14, 2025, before the market opens.

The report will be a critical checkpoint for investors, revealing how the healthcare giant is navigating the significant headwind of biosimilar competition for its blockbuster drug, Stelara, while pushing for growth in its other key franchises and its burgeoning MedTech division.

Earnings per share (EPS): Analysts are forecasting a solid quarter, with a consensus estimate for earnings per share (EPS) at $2.77, which would represent a robust 14.5% increase year-over-year.

Revenue: Revenue is expected to reach approximately $23.74 billion, a 5.6% rise from the same period last year. This anticipated growth, despite the Stelara challenge, underscores the diversified nature of J&J's portfolio

J&J's Diversified Strength Shines in Q2 as Raised Guidance Signals Life Beyond Stelara

Johnson & Johnson (JNJ) delivered a robust second-quarter 2025 performance that showcased the resilience of its diversified business model, successfully weathering the initial, significant impact of biosimilar competition for its blockbuster immunology drug, Stelara.

The healthcare giant beat analyst expectations, reporting sales of $23.7 billion, a 5.8% year-over-year increase, and an adjusted earnings per share (EPS) of $2.77.

The headline numbers, while strong, tell a deeper story of strategic execution. The Innovative Medicine segment posted operational growth of 3.8%, reaching over $15 billion in quarterly sales for the first time. This achievement was particularly noteworthy as it absorbed an approximate 1,170 basis point headwind from the steep decline in Stelara sales following the loss of exclusivity.

The erosion of this former pillar was effectively offset by the stellar performance of other key drugs. The oncology portfolio was a standout, with Darzalex sales jumping 23% to $3.5 billion. Other growth drivers included immunology drug Tremfya (up 30%) and neuroscience treatment Spravato (up 53%).

Meanwhile, the MedTech division continued its strong momentum, delivering 6.1% operational growth with sales of $8.5 billion. The segment's performance was bolstered by a more than 22% operational sales growth in the Cardiovascular portfolio, highlighting the success of recent strategic acquisitions and new product launches.

Lessons Learned from Confident Guidance

Perhaps the most significant takeaway from the quarter was Johnson & Johnson's decision to raise its full-year 2025 guidance, a clear signal of confidence from management. The company now projects adjusted operational sales growth to be between 3.2% and 3.7% (up from 2.0% to 3.0%) and adjusted EPS in the range of $10.80 to $10.90 (up from $10.50 to $10.70). This upward revision, in the face of the Stelara patent cliff, offered several key lessons for investors:

The Power of a Diversified Portfolio: The Q2 results are a masterclass in the value of diversification. J&J proved it is not a one-product company. The ability of the broader Innovative Medicine portfolio, particularly in oncology and other areas of immunology, to absorb the Stelara shock is a powerful testament to the depth of its pipeline and commercial execution.

MedTech is a Formidable Growth Engine: The consistent and strong performance of the MedTech segment underscores its critical role in J&J's future. It provides a stable and growing revenue stream that is less susceptible to the binary risks of patent cliffs. Investors can expect continued strategic investment in this high-growth area.

Successfully Navigating the Patent Cliff: Management's guidance indicates that the worst of the Stelara headwind has been successfully modeled and managed. By raising the outlook, the company is signaling that the growth from its other assets and new launches will more than compensate for the decline of its former blockbuster, and that this positive trajectory will continue and even accelerate in the second half of the year.

Confidence in the Pipeline: The raised guidance is not just about the performance of current products; it's a vote of confidence in the near-term pipeline. Management highlighted anticipated "game-changing approvals and submissions" in key areas like oncology and cardiovascular, suggesting new revenue streams are on the horizon to fuel future growth. This forward-looking optimism suggests that the company is proactively managing its product lifecycle and is well-positioned for sustained growth.

Key Metrics for Investors to Watch:

Investors will be dissecting the report for insights into the company's underlying health and future growth trajectory. Here are the crucial metrics to monitor:

1. Innovative Medicine Segment Sales: This segment remains the primary revenue driver, and its performance will be under the microscope.

* Total Segment Revenue: Wall Street is looking for a figure around $15.25 billion.

* Key Drug Performance: The focus will be on the growth of J&J's core products to see if they can offset the expected decline in Stelara sales.

* Darzalex (Multiple Myeloma): Consensus sales estimate is approximately $3.63 billion. Continued strong growth is vital.

* Tremfya (Psoriasis): Expected sales of around $1.3 billion. Performance here is key as it competes in the immunology space.

* Erleada (Prostate Cancer): Forecasts are near $947 million.

* The Stelara Impact: With multiple biosimilars now on the market, the magnitude of the sales decline for Stelara (estimated around $1.54 billion for the quarter) will be a major focus. The company's commentary on the erosion curve will be critical.

* New Product Momentum: Sales figures for newer drugs like Carvykti (oncology), Tecvayli, and Talvey will be scrutinized for their growth trajectory and potential to become future blockbusters.

2. MedTech Segment Growth: This division is a key pillar of J&J's growth strategy, and strong performance is anticipated.

* Total Segment Revenue: The consensus estimate is $8.35 billion.

* Cardiovascular Strength: Look for continued strong contributions from the acquisitions of Abiomed and Shockwave Medical, which have bolstered the company's position in this high-growth area.

* Surgical and Vision Performance: Increased procedural volumes and the adoption of new products are expected to drive solid results in these sub-segments.

3. Full-Year Guidance: Any adjustments to the company's full-year 2025 forecast will significantly influence the stock's post-earnings movement. Management's outlook for the fourth quarter and initial commentary on 2026 will be pivotal in shaping investor sentiment, especially concerning the ongoing impact of the Stelara patent cliff and the integration of recent acquisitions.

4. Profit Margins: Investors will assess the company's ability to manage costs and maintain profitability amidst inflationary pressures and the costs associated with new product launches and acquisitions.

Johnson & Johnson (JNJ) Price Target

Based on 25 analysts from Tiger Brokers offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $187.98 with a high forecast of $213.00 and a low forecast of $155.00. The average price target represents a -1.44% change from the last price of $190.72.

Short-Term Trading Opportunities Post-Earnings:

Johnson & Johnson has a long history of beating earnings expectations, which is often priced into the stock. However, the level of uncertainty around the Stelara sales erosion creates potential for post-earnings volatility.

Bullish Scenario: A significant beat on both EPS and revenue, coupled with stronger-than-expected sales from Darzalex and Tremfya that demonstrably offset a less-severe-than-feared decline in Stelara sales, could propel the stock higher. Positive revisions to the full-year guidance would be a major catalyst. Traders might consider short-term call options or buying the stock if it breaks through key resistance levels following the announcement.

Bearish Scenario: A revenue or EPS miss, or even an in-line result with a steeper-than-anticipated drop in Stelara sales, could disappoint investors. Any signs of slowing growth in the MedTech segment or a downward revision to the company's guidance could trigger a sell-off. In this case, put options or short-selling could be considered by traders with a high-risk tolerance.

Navigating the Nuance: The most likely scenario is a complex report with both positive and negative elements. For instance, strong MedTech performance might be overshadowed by cautious commentary on the pharmaceutical pipeline. Traders should listen closely to the investor conference call at 8:30 AM ET for management's tone and detailed explanations, which often have a greater impact on the stock's direction than the initial headline numbers. The reaction to the guidance will be particularly telling.

Technical Analysis - Exponential Moving Average (EMA)

JNJ has managed to suffer only a small decline from last Friday’s major pullback and it continue to stay well above the 12-EMA with a positive RSI momentum, but with more details that might be released for the increase of tariffs for China, we need to understand that China consumers are also using JNJ products pretty significantly.

So the impact of tariffs cannot be overlooked as there might be concern from investors before its earnings release on 14 Oct, so I am expecting a slight pullback when JNJ start trading on Monday (13 Oct).

Summary

Analysts expect EPS of about $2.77, up ~14.5% year-over-year, and revenue of ~$23.74 billion (≈ +5.6% YoY)

Growth is forecast across both business segments:

Innovative Medicines (~$15.25B), with strong momentum in oncology and neuroscience.

MedTech (~$8.35B), buoyed by cardiovascular devices and surgical products.

Risks include pressure from biosimilar competition (notably for Stelara) and margin impacts from tariffs and foreign-exchange headwinds.

Positive catalysts: J&J recently raised full-year sales and EPS guidance and analysts have upgraded target prices, reflecting confidence in its pipeline and MedTech recovery.

Appreciate if you could share your thoughts in the comment section whether you think JNJ would show the impact of tariffs in its upcoming earnings and also the share price might take a beating with President Trump announcement of tariffs increase on China.

@TigerStars @Daily_Discussion @Tiger_Earnings @TigerWire @MillionaireTiger appreciate if you could feature this article so that fellow tiger would benefit from my investing and trading thoughts.

Disclaimer: The analysis and result presented does not recommend or suggest any investing in the said stock. This is purely for Analysis.